Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Stefan Sleijfer"'
Autor:
Antoine Italiano, Christian Rothermundt, Jean-Yves Blay, Stefan Sleijfer, Aisha Miah, Bernd Kasper, Silvia Stacchiotti, Attila Kollár, Sebastian Bauer, Galina Farina Fischer, Paul Martin Putora, Viktor Grünwald, Lars H. Lindner
Publikováno v:
Oncologist, 23(4), 461-467. AlphaMed Press
Background The management of localized extremity soft tissue sarcomas (STS) is challenging and the role of pre- and postoperative chemotherapy is unclear and debated among experts. Materials and Methods Medical oncology experts of the European Organi
Autor:
Fleur Weeber, Christa G Gadellaa-van Hooijdonk, Stefan Sleijfer, Marco J. Koudijs, Edwin Cuppen, Neeltje Steeghs, Paul J. van Diest, Michel M. van den Heuvel, Ron H.J. Mathijssen, Wouter B. Veldhuis, Annette H. Bruggink, Isaac J. Numan, Maja J.A. de Jonge, Jan H.M. Schellens, Sander Bins, Emile E. Voest, Geert A. Cirkel, Erik van Werkhoven, Rob J. de Knegt, Stefan M. Willems, Marlies H.G. Langenberg, Martijn P. Lolkema
Publikováno v:
Oncologist, 22(1), 33-40. AlphaMed Press
Oncologist, 22, 1, pp. 33-40
Oncologist, 22, 33-40
Oncologist, 22, 1, pp. 33-40
Oncologist, 22, 33-40
Background The discovery of novel biomarkers that predict treatment response in advanced cancer patients requires acquisition of high-quality tumor samples. As cancer evolves over time, tissue is ideally obtained before the start of each treatment. P
Autor:
Johanneke E.A. Portielje, Mark-David Levin, Monique M.E.M. Bos, Stefan Sleijfer, Jan C. Drooger, Agnes Jager, Joost van Rosmalen, Elisabeth M. P. Elsten, Hánah N. Rier, Albert‐Jan Ten Tije, Paul de Jong
Publikováno v:
Oncologist, 22(8), 901-909. AlphaMed Press
Background Survival of patients with human epidermal growth receptor 2 (HER2)-positive metastatic breast cancer (MBC) has improved dramatically since trastuzumab has become available, although the disease eventually progresses in most patients. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::406b3a20ae4b55e94e4f7b28e1a8faf1
https://europepmc.org/articles/PMC5553959/
https://europepmc.org/articles/PMC5553959/
Publikováno v:
Oncologist, 10, 833-841. AlphaMed Press
Learning Objectives After completing this course, the reader will be able to: Discuss the current status of the chemotherapeutic treatment of advanced soft tissue sarcomas in adult patients.Explain the pitfalls in trial design when reading published
Autor:
Stefan Sleijfer
Angiosarcomas account for2% of all soft tissue sarcomas. This subtype is one of the most aggressive forms of soft tissue sarcoma. The prognosis for angiosarcoma patients in the advanced phase remains poor with current cytotoxic agents (progression-fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af9bad9cf6d32a7be2d29883ed31ba4b
https://europepmc.org/articles/PMC3286160/
https://europepmc.org/articles/PMC3286160/
Autor:
Ron H.N. van Schaik, Marianne van Fessem, Paul L A van Daele, Floris A. de Jong, Alex Sparreboom, Fleur E. van de Geijn, Jessica M. van der Bol, Stefan Sleijfer, Ron H.J. Mathijssen, Jaap Verweij
Publikováno v:
Oncologist, 15(10), 1063-1072. AlphaMed Press
Objective. Mannose-binding lectin (MBL) is important in the innate immune response. MBL2 gene polymorphisms affect MBL expression, and genotypes yielding low MBL levels have been associated with an elevated risk for infections in hematological cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78c39c2f76678487617bfabe9fd1a0db
https://europepmc.org/articles/PMC3227891/
https://europepmc.org/articles/PMC3227891/